The Texas Science and Technology Association focuses on innovation -driven and talent strong cities, comprehensively implements the deployment of provincial and municipal scientific and technological innovation work, promotes the city's pilot cities for the "science and technology innovation China", and organizes the "innovation experts" preaching activities of Texas enterprises A large number of enterprises that are innovative, pursuing the extreme, and ingenious companies have been selected.

       In the selection of "Innovation Talents" in Texas Enterprises in 2023, Liu Baofeng, senior deputy general manager of our company (Shandong Xinbo Drug Research Co., Ltd.), won this honor!

As a high -tech CRO company specializing in preclinical evaluation, we know that technological innovation is the foundation of the company. Therefore, as the deputy general manager of the company, I actively lead the scientific research team to develop business and establish various special technologies. With the discovery of new targets and drug development, many innovative drugs stand out. How to effectively and comprehensively evaluate the safety and effectiveness of innovative drugs has become the goal of GLP people.
       For drugs with short clinical half -life and highly toxicity, clinical clinical need to get intravenous injection. We simulated the technology of establishing a sober rats and dogs for 3 months, and successfully established the safety evaluation of clinical long -term venous injection drugs. The platform, and uses this technology platform to complete the pre -clinical safety evaluation of 2 drugs, filling the gap in domestic research and development.

Clinical long -term medication safety evaluation platform

In order to better carry out the evaluation of nucleic acid drugs, we establish a molecular biology laboratory and explore and establish a method of macromolecular detection. This platform can not only serve the evaluation of nucleic acid drugs, but also be used for therapeutic vaccine and preventability Evaluation of vaccine. At present, we have used the platform to complete the evaluation of 1 small nucleic acid treatment drugs, 5 therapeutic vaccines, and several preventive vaccines. Among them, the number and experience of the treatment of therapeutic vaccines ranked first in the country.

Pathological diagnosis is the gold standard for determining the toxicity of drugs. From the market demand, we develop special materials and various immunohistochemical dyeing technologies and other special dyeing technologies. In 2022, it obtained the "toxic pathological examination" capacity verification certificate organized by the China Qualified Evaluation State Appraisal Committee, marking that our professional ability of pathological diagnosis has been recognized by the state, and the test report issued is authoritative and credible.
       In terms of business operation management, I pay special attention to team building. With 10 years, the company's scale has expanded by more than 4 times, and the business volume has increased several times. In 2022, preparation safety tests are relatively concentrated. We reasonably arrange experiments to carry out experiments to carry out 8 varieties per week to increase to 12 varieties, ensure the progress of R & D, and bring a 50%income to the company.
       Many years of work has allowed me to realize that as a high -tech company, only technological innovation and breakthroughs are continuously served according to market demand can we better serve the new drug research and development of new drug research and development, and be invincible in market competition.



Introduction to Liu Baofeng:
     Liu Baofeng, senior deputy general manager of Shandong Xinbo Drug Research Co., Ltd., deputy director of the Drug Safety Evaluation Research Center, executive member of the Safety Evaluation Professional Committee of the Chinese Academy of Chinese Medicine, member of the Shandong Poison Society, and executive director of the Shandong Experimental Animal Society.
I have been engaged in drug safety evaluation for 21 years. I have accumulated rich research experience in the safety evaluation of innovative drugs such as chemical drugs, Chinese medicine and biological products. Multiple generic drugs and more than 50 vaccines clinical safety evaluation work, and participated in the writing of "Drug Alert and Safety Evaluation". Especially since the outbreak of the new crown epidemic, through its own rich experience, targeted clinical safety evaluation and design is conducted for the characteristics of different new crown vaccines, and the vaccine evaluation is completed within the shortest experimental cycle. Essence As of now, a total of more than 30 clinical safety evaluations of more than 30 new crown vaccines have been completed, and many of them have obtained clinical permits and have entered clinical trials. He has won the "First Prize of the Excellent Achievement of the Shandong Enterprise Technology Innovation Award", "2018-2020, the second prize of the 15th Natural Science Outstanding Academic Achievement Award of Natural Sciences in Texas", "the third prize of the Texas Science Progress Award" Honor.